1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,000 | 0,000 | 10.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Tevogen Bio Holdings Inc. - 10-K/A, Annual Report | - | SEC Filings | ||
| 22.04. | Tevogen Bio Holdings Inc. - 8-K, Current Report | - | SEC Filings | ||
| 31.03. | Tevogen Bio Holdings Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 26.03. | Tevogen Bio Inc: Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth | 268 | GlobeNewswire (Europe) | Potential transaction expected to add $20M+ in revenue and support double-digit growth, further strengthening Tevogen's position in oncology, rare diseases, and medical devicesTarget CRO operates... ► Artikel lesen | |
| TEVOGEN BIO Aktie jetzt für 0€ handeln | |||||
| 25.03. | Tevogen Bio erfüllt nach Aktienzusammenlegung wieder Nasdaq-Anforderungen | 3 | Investing.com Deutsch | ||
| 25.03. | Tevogen Bio Holdings Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 25.03. | Tevogen Bio Inc: Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement | 183 | GlobeNewswire (Europe) | WARREN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) received written notice (the "Notification Letter") from The Nasdaq Stock Market... ► Artikel lesen | |
| 13.03. | Tevogen Bio Inc: Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization | 359 | GlobeNewswire (Europe) | Lead investor confirmed his intention to maintain his current shareholdings.Company does not anticipate using more than 1% of our authorized shares, including placement through the ATM, over the next... ► Artikel lesen | |
| 13.03. | Tevogen Bio Inc: Tevogen.AI Reports Advancements in PredicTcell Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure | 405 | GlobeNewswire (Europe) | WARREN, N.J., March 13, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced performance advancements for its artificial intelligence platform... ► Artikel lesen | |
| 11.03. | Tevogen Bio Inc: Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform | 2 | GlobeNewswire (USA) | ||
| 09.03. | Tevogen Bio Inc: Tevogen Names Leadership Team to Execute Diversified Growth Strategy | 383 | GlobeNewswire (Europe) | WARREN, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced the appointment of interim leaders across its core business verticals... ► Artikel lesen | |
| 06.03. | Tevogen Bio Inc: Letter to Shareholders from CEO Dr. Ryan Saadi | 667 | GlobeNewswire (Europe) | WARREN, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN). Dear Shareholders, As we continue executing on Tevogen's long-term strategy to evolve... ► Artikel lesen | |
| 06.03. | Tevogen Bio Explores Buyout To Boost Generics Platform | 6 | Benzinga.com | ||
| 06.03. | XFRA G280: AUSSETZUNG/SUSPENSION | 271 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILTEVOGEN BIO HLDGS... ► Artikel lesen | |
| 06.03. | XFRA NEW INSTRUMENTS AVAILABLE ON 06.03.2026 | 375 | Xetra Newsboard | The following instruments on XETRA do have their first trading 06.03.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 06.03.2026
Aktien
1 CA3027351053 Fab-Form Industries... ► Artikel lesen | |
| 05.03. | Tevogen Bio Inc: Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical | 242 | GlobeNewswire (Europe) | WARREN, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced that it has entered into a signed, non-exclusive, non-binding Letter... ► Artikel lesen | |
| 05.03. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 05.03.2026 | 550 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 05.03.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 05.03.2026.ISIN NameCA37640A4028 GLACIER... ► Artikel lesen | |
| 05.03. | XFRA ISIN CHANGE | 395 | Xetra Newsboard | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenCA37640A4028 Glacier Lake Resources Inc. 05.03.2026 CA83058E1060 Glacier Lake Resources Inc. 06.03.2026 Tausch 2,4:1US88165K1016 Tevogen... ► Artikel lesen | |
| 04.03. | Tevogen approves 1-for-50 reverse share split | 3 | Seeking Alpha | ||
| 04.03. | Tevogen Bio Inc: Tevogen Announces Reverse Stock Split | 234 | GlobeNewswire (Europe) | WARREN, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced that its Board of Directors (the "Board") has approved a reverse... ► Artikel lesen |
1 2 3 4 Weiter >>
63 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 29,035 | +1,84 % | QIAGEN bremst Erwartungen: QuantiFERON schwächelt, Hoffnung auf zweites Halbjahr | QIAGEN startet schwach ins Jahr: Umsatz stagniert, QuantiFERON belastet - Prognose gesenkt, Hoffnung liegt auf stärkerem zweiten Halbjahr. Der Diagnostik- und Life-Sciences-Konzern QIAGEN ist verhalten... ► Artikel lesen | |
| AMGEN | 295,45 | +0,14 % | Amgen hebt Jahresprognose an - Quartalszahlen etwa wie erwartet | THOUSAND OAKS (dpa-AFX) - Der US-Biotechkonzern Amgen blickt trotz zunehmender Konkurrenz zuversichtlicher auf das laufende Jahr. 2026 werde der Umsatz bei 37,1 bis 38,5 Milliarden Dollar liegen, teilte... ► Artikel lesen | |
| NOVAVAX | 7,030 | +4,15 % | FOMO an der Wall Street: Novavax meldet überraschenden Gewinn - Aktie schießt zweistellig hoch | © Foto: picture alliance / Ulrich Baumgarten | Ulrich BaumgartenEin Ergebnis, das niemand erwartet hatte, gepaart mit neuen Big-Pharma-Deals: Novavax sorgt für FOMO an der Wall Street. Wie lange hält... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 21,930 | 0,00 % | Morning Market Movers: Super Micro Computer, Bimergen Energy, Palatin Technologies, Intellicheck See Big Swings | HONG KONG (dpa-AFX) - At 7:40 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 600,40 | -0,35 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| INOVIO PHARMACEUTICALS | 0,951 | -0,89 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | Biologics License Application (BLA) for INO-3107 accepted for review under the Accelerated Approval Program as a potential treatment for adults with Recurrent... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,390 | 0,00 % | COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | TORONTO, ONTARIO, March 25, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) ("COSCIENS" or the "Company"), a life science company focused on the development of natural... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 46,680 | +1,59 % | BioMarin Pharmaceutical Inc.: BioMarin Completes Acquisition of Amicus Therapeutics | Acquisition Adds Galafold® (migalastat) for Fabry Disease and Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) for Pompe Disease to BioMarin's Commercial... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 61,20 | -2,27 % | JPMorgan initiates Arrowhead Pharma stock coverage with overweight rating | ||
| XOMA ROYALTY | 35,400 | +1,14 % | XFRA X0M1: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILXOMA ROYALTY DL... ► Artikel lesen | |
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-K, Annual Report | ||
| PHIO PHARMACEUTICALS | 1,140 | -6,56 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series | King of Prussia, Pennsylvania--(Newsfile Corp. - April 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its... ► Artikel lesen | |
| ORAGENICS | 0,600 | 0,00 % | Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation | SARASOTA, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal... ► Artikel lesen | |
| INSMED | 116,34 | +0,10 % | INSMED INC - Stabilität als Basis für den nächsten Impuls | ||
| SWEDISH ORPHAN BIOVITRUM | 40,140 | +0,35 % | Swedish Orphan Biovitrum AB Bottom Line Climbs In Q1 | STOCKHOLM (dpa-AFX) - Swedish Orphan Biovitrum AB (SWOBY) revealed a profit for its first quarter that Increases, from last yearThe company's bottom line totaled SEK1.318 billion, or SEK3.77... ► Artikel lesen |
Das Unternehmen TEVOGEN BIO HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -1,28 % bei einem Aktienkurs von 6,535 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TEVOGEN BIO HOLDINGS INC finden Sie auf Wallstreet Online.